Background. Growth retardation in paediatric end-stage renal disease (ESRD) has a serious impact on adult life. It is potentially treatable with recombinant growth hormone (rGH). In this study, we aimed to quantify the variation in rGH policies and actual provided care in these patients across Europe. Methods. Renal registry representatives of 38 European countries received a structured questionnaire on rGH policy. Crosssectional data on height and actual use of rGH on children with ESRD aged <18 years were retrieved from the ESPN/ERA-EDTA Registry. Results. In 21 (75%) of 28 responding countries, rGH is reimbursed for children with ESRD. The specific conditions for reimbursement (minimum age, maximum age and chronic kidney disease stage) vary considerably. Mean height standard deviation scores (SDS) at renal replacement therapy (RRT) [95% confidence interval (CI)] were significantly higher in countries where rGH was reimbursed −1.80 (−2.06; −1.53) compared with countries in which it was not reimbursed [−2.34 (−2.49;−2.18), P < 0.001]. Comparison of the mean height SDS at onset of RRT and final height SDS yielded similar
therefore be considered as a marker of quality of paediatric renal care.
Treatment of growth failure in paediatric ESRD consists of correcting any nutritional, water and salt deficiencies as well as metabolic abnormalities. In case of persistent growth failure, recombinant growth hormone (rGH) might be indicated [7] . Although rGH use is found to be safe and efficacious in children with ESRD [8] [9] [10] [11] [12] , its use has been reported as limited [13] .
Although some national guidelines are available, general European guidelines on rGH use in paediatric ESRD are lacking and, therefore, the care provided to growth-retarded children could differ between countries. Previous studies have highlighted the variation in management of children with ESRD between European countries [14] [15] [16] . As the use of rGH is expensive, reimbursement and subsequently the possibility to prescribe rGH to every patient may vary per country. These factors may lead to different policies and actual provided care per country, which could possibly explain the variation in the extent of growth retardation among the European countries [17] . Furthermore, because of the lack of international guidelines, variation might occur in the chronic kidney disease (CKD) stage in which rGH therapy is initiated-only at the time of dialysis or already in CKD stage 2-4-in the age range in which rGH is being provided, as well as in the measures used to identify growth retardation, for example short stature or a decline in growth velocity.
In this study, we aimed to describe the variation in growth hormone policies in paediatric nephrology patients across European countries and relate these policies to outcomes, including height at start of renal replacement therapy (RRT), height during childhood RRT and final height by using data from the ESPN/ERA-EDTA registry.
M AT E R I A L S A N D M E T H O D S

Data sources
We developed a structured questionnaire on growth hormone policies in European paediatric renal care. To ensure content validity, we used input from four paediatric nephrologists from different countries. An overview of all questions in the questionnaire is shown in Appendix 1.
The questionnaire was sent to the paediatric renal registry representatives in 38 countries in the European region.
Cross-sectional data on height of children on RRT were retrieved from the ESPN/ERA-EDTA Registry. Within this registry, demographic data on all European children starting RRT are collected annually. Moreover, a variable set of data on anthropometric, clinical and medication-related parameters are collected [18] . For this study, height data collected from 2007 onwards were used.
Definition of variables
Standard deviation scores (SDS) for height were calculated according to recent national growth charts whenever available or according to the recently developed Northern and Southern European growth charts [17] . SDS was defined as the following: (individual patient height-mean height for age-and sexrelated healthy peers)/SD of height for age-and sex-related healthy peers.
Macro-economic indicators were obtained from the WorldBank [19] and expressed as Gross Domestic Product (GDP) per capita. We compared national growth hormone policies with actual use of rGH and with the percentage of children with a short stature defined as height SDS of −2 or below. Within the registry data on rGH use are limited, and no data are available on the duration of rGH treatment. Therefore, to study the effect of actual rGH use, we calculated the percentage of patients with a short stature that used rGH (yes/no) during 5 years of follow-up (2007-12, whenever available). Data on actual rGH use of each specific country was included in the analyses when data on both rGH use and growth parameters was available for at least 50% of the patients. The paediatric renal registry representatives were asked in a qualitative manner to explain any differences between the actual provided care of rGH and the number of eligible patient for rGH.
Statistical analysis
In the ESPN/ERA-EDTA registry, the number of height measurements differed between patients and countries. To correct for the correlation of measurements within the same patient, we used linear mixed models. Only countries for which height data were available for a sufficient number of patients (at least 10 or all patients in case of a particularly small country) were included in the analyses. χ 2 analysis and Kruskal-Wallis one-way analysis of variance were used to compare differences between groups. For Italy and the FYR of Macedonia, only height data on dialysis patients were available from the registry. Therefore, to test the possible confounding effect -of country policy in combination with information only on the (shorter) dialysis patients-we performed a sensitivity analysis excluding these patients from these countries. In order to adjust for differences in economic indicators across countries, we included GDP per capita in our analyses. Values are presented as mean (SE) unless stated otherwise. P values of <0.05 were considered statistically significant. All analyses were performed in SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA) and SPSS version 20 (IBM, SPSS Statistics 20, Chicago, IL, USA).
R E S U LT S
Policies in rGH use
Twenty-eight of 38 (response rate 74%) of the countries completed the questionnaire. The mean height SDS at start of RRT, mean height SDS during RRT and final height SDS by country are presented in Table 1 .
In 21 (75%) of 28 countries, rGH was reimbursed for children with CKD, and in 7 there was no reimbursement under any circumstances, except in 2 of these countries which indicated that, in exceptional cases (e.g. in case of strict endocrinological criteria being satisfied), its use was allowed.
Of the 21 countries where rGH was reimbursed, 15 reported to have a national policy on rGH use in CKD. Policies were based on either international guidelines (50%), national consensus (32%), local consensus among either paediatric nephrologists or paediatric endocrinologists (25%), government policies (11%) or health insurance companies (18%). The minimum age to prescribe rGH varied between 0 and 60 months, whereas the maximum age for prescription ranged from 14 years to no maximum age. Countries were either allowed to prescribe growth hormone in CKD stage 1-4 and when glomerular filtration rate was reduced in transplanted patients or in CKD patients only (not on dialysis or after renal transplantation). One country was allowed to prescribe growth hormone in dialysis patients only. An overview of all reported policies is presented in Appendix 2.
Height SDS criteria for prescribing rGH varied between −1.88 and −3 SDS. Two countries only used height SDS as a criterion, whereas 8 countries used either height SDS and/or a stable or decrease in height SDS (stable or decrease of >0.25 SDS in the previous year) and/or growth velocity (>1 SDS decrease in growth velocity) as a criteria and 11 countries specified no height criteria for prescribing rGH.
Differences between policies in relation to height SDS and economic indicators Policies and outcomes are shown in Table 2 . GDP was significantly higher in countries with rGH reimbursement (31.8) when compared with countries without rGH reimbursement (17.0, P = 0.01). GDP was positively associated with mean height SDS during RRT (β = 0.013), height SDS at start of RRT (β = 0.003) and final height SDS (β = 0.009). This association was only statistically significant for mean height SDS during RRT (P < 0.001).
Mean height SDS (95% CI) was significantly higher in countries where rGH was reimbursed [−1.80 (95% CI −2.06 to −1.53)] compared with countries where rGH was not reimbursed [−2.34 (95% CI: −2.49 to −2.18), P < 0.001]. Similar results were obtained when comparing mean height SDS at the start of RRT and final height SDS. There were no height differences between countries that were allowed to prescribe rGH among CKD patients and dialysis only and among CKD, dialysis and Tx patients ( Table 2) .
Effect of age limitation of rGH prescription. When categorizing the minimum age at start of rGH, mean height SDS was significantly lower in countries who were allowed to prescribe rGH under the age of 12 months (mean height SDS: −1.98) versus those allowed to prescribe from 12-24 months (mean height SDS: −1.93) and from 24 months and older (−1.52 SDS, P < 0.001).
When looking at the upper age limits, mean final height SDS was 0.63 SDS lower (P < 0.001) in countries who were allowed to prescribe rGH in children over 18 years, when compared with countries who were not allowed to prescribe rGH in children over 18 years of age.
Height criteria. Mean height SDS tended to be lower in countries who were allowed to prescribe rGH based on height SDS alone or based on height SDS and growth velocity when compared with countries who were allowed to prescribe rGH based on either height SDS or a stable/decrease in growth velocity ( Table 2 ). 
O R I G I N A L A R T I C L E
V a r i a t i o n s i n g r o w t h h o r m o n e p o l i c i e s i n E u r o p e CKD stage. Countries were allowed to prescribe rGH at different stages of CKD, varying from CKD stage 1-5 to CKD stage 4-5. There were very small differences in mean height SDS at start of RRT by CKD stage, but there was an inverse relationship between CKD stage and height at start of RRT; height SDS was significantly higher in countries who were allowed to prescribe rGH in CKD stage 4-5 (−1.48, 95% CI: −1.85 to −1.10) or stage 3-5 (−1.33, 95% CI: −1.51 to −1.14) when compared with countries where physicians were allowed to prescribe rGH from CKD stage 1 onwards (−1.94, 95% CI: −2.58 to −1.29).
Actual provided care. We were able to retrieve the percentage of rGH use between 2007 and 2011 in 13 of the 28 countries. We calculated the percentage of children who were eligible for rGH use. Overall rGH use between 2007 and 2011 in dialysis and transplantation was 21.7 and 5.5%, respectively, and major country differences were observed (Tables 3 and 4) . A total of 45.9% of dialysis and 38.9% of transplant patients had a short stature (height SDS less than −2) and would therefore be eligible for receiving rGH. In all countries, the actual use of rGH was lower than the number of children eligible for rGH: only 26.0% of short dialysis and 8.9% of short transplant patients actually received rGH. When applying country-specific criteria to define short stature, similar figures were observed (Tables 3 and 4) .
Physicians stated that the difference between actual rGH use and percentage of children eligible for rGH was due to several factors: patients refused treatment, improving nutritional intake and metabolic bone disease had priority over starting rGH, dialysis adequacy was sub-optimal, and patients were suffering from severe uncontrolled hyperparathyroidism. In addition, physicians stated that delayed prescription could occur when the responsibility for prescribing rGH was under control of the endocrinologist. There was no association between the percentage of rGH use and mean height SDS during RRT ( Figure 1A and B) or percentage of rGH use and final height in both dialysis (β = 0.02, P = 0.28; Figure 1C ) and transplantation (β = 0.03, P = 0.25; Figure 1D ).
D I S C U S S I O N
In this paper, we demonstrated a considerable variation in growth hormone policies across 28 countries in Europe. We found that total absence of reimbursement of rGH indeed was associated with a more compromised final stature of ESRD children. However, specific restrictions to a basic reimbursement policy did not influence final stature or height at RRT. On the other hand, we found that the actual rGH prescription in patients who were eligible for rGH was remarkably low and differed substantially among countries. Total absence of rGH reimbursement was only apparent in 7 of 28 countries. These were all countries with a relatively low GDP. Two of these countries used the escape of strict endocrinological criteria, which makes prescription in this category of patients virtually impossible. As in CKD, GH levels are usually normal and GH stimulation tests are often positive [10, 20] . Two countries stated not being allowed to prescribe rGH in transplanted children. For one country, this was due to a fear of graft loss in rGH treatment in transplanted children with already a shortage in available donor kidneys. Although older studies indeed suggest rGH treatment in transplanted children to be associated with an increased risk of allograft loss [21, 22] , more recent studies did not show an increased risk of allograft loss or adverse events in children treated with rGH after renal transplantation [23] [24] [25] [26] [27] [28] . Therefore, the policies in which rGH is not allowed in transplanted children might need to be reconsidered.
We found a large variation in the minimum age for prescribing rGH, which was associated with mean (final) height SDS; mean height SDS was lowest in the countries who were allowed to prescribe rGH before 24 months of age. This is surprising, unless the policy is adapted to the mean (final) height SDS in those countries, where the policy is to treat children at a younger age in order to achieve a better final height. In interpretation of this association, we need to take into account that we performed a cross-sectional study and that it is impossible to determine whether rGH treatment preceded the outcome (final height) or the other way around. Data from Mencarelli et al. [29] and a study by Fine et al. [9] showed a significant improvement in height SDS in growth-retarded children with chronic kidney failure when treated with rGH at a young age. Nevertheless, other studies [30, 31] hypothesized that growth failure at a young age is mainly a reflection of nutritional influences and could be treated conservatively. The Kidney Disease Outcomes Quality Initiative (KDOQI) [7] recommends frequent monitoring of nutritional deficiencies and adequate caloric intake before starting rGH therapy in children aged under 3 years. Although most nephrologists probably follow the KDOQI guidelines on adequate caloric intake, there is still much debate about the definition of 'optimal feeding' and hence on the exact indication for growth hormone therapy. Data on supplemental 
O R I G I N A L A R T I C L E
V a r i a t i o n s i n g r o w t h h o r m o n e p o l i c i e s i n E u r o p e feeding are not available from the registry. Therefore, we were not able to investigate this subject. Height criteria for initiating rGH therapy also vary between different guidelines. The KDOQI guidelines [7] recommend considering rGH in children with a height SDS less than −1.88 or height for age <3rd percentile and a growth velocityfor-age SDS less than −1.88 or growth velocity-for-age <3rd percentile. The CARI guidelines [32] recommend offering rGH therapy to all children with a height <25th percentile and a growth velocity <25th percentile. Within our study, height criteria for prescribing rGH varied considerably across countries. We found more liberal policies based on either decreased height SDS or growth velocity were associated with a higher mean final height than the more restricted policies.
Children with a functioning graft have a more favourable outcome when compared with children who are on dialysis for a longer time period. Since Italy provided only data of children on dialysis, the same analyses were performed excluding the data from Italy. This sensitivity analyses showed no significant differences in the results. Therefore, we think that the results of this study are not distorted to a large extent by data of children on dialysis.
Whether the differences in outcome are merely the effect of differences in policies remains unclear, since we had limited data on actual rGH use. In keeping with previous studies, we did show that the majority of children with a short stature did not use growth hormone in the preceding period. In the UK, it has been estimated that although 29% of the children on a renal transplant with impaired renal function and 41% of the children on dialysis suffered from growth retardation, <5% of the children receive rGH treatment. Also, the NAPRTCS study found that rGH is used in only a minority (33 and 3% of children on dialysis and on a renal transplant, respectively) [33] . Recently, the Chronic Kidney Disease in Children (CKiD) study group showed that only 23% of children with severe growth retardation (height SDS < −1.88) receive growth hormone therapy [34] . These findings correspond with the results of our study.
There were differences between policies and actual provided care, possibly explained by both doctor-and patient-related factors, such as patients refusing rGH therapy. Improving nutritional intake and treatment of metabolic bone disease sometimes were prioritized over starting rGH. Although improving nutritional intake has proven to be beneficial for linear growth, dietary intervention is most successful in infancy [35, 36] . Therefore, in older children, rGH therapy might be preferred over improving nutritional intake.
Also, non-adherence might be an obstacle in prescribing rGH, as demonstrated in an earlier study by the CKiD group where self-reported non-adherence to rGH, defined by missing at least one dose within 7 days, was 25% [34] . Another study by Greenbaum et al. [37] explored the obstacles to prescribing rGH in children with CKD. They found several reasons why children did not receive growth hormone, such as psychosocial reasons (family refusal, non-adherence and 'overwhelmed' family) in 30% of the cases whereas, in 25% of cases, no reason could be identified. Possibly, the fact that many children eligible for rGH are awaiting kidney transplantation might contribute to the extremely low use of rGH in our population. After transplantation, a good catch-up growth is expected in case of good renal function [38] . In anticipation of such a situation, physicians might have decided not to start rGH treatment. The extremely low use of rGH after renal transplantation might be caused by the fear of triggering rejection episodes. Studies in transplant recipients did, however, not show an association between the use of rGH and rejection episodes [24-26, 28, 39] . Finally, under-reporting of rGH use in the registry might at least partly explain the difference between rGH use and percentage of children on rGH.
The reimbursement of rGH affected height outcome, whereas differences between policies in those countries in which rGH was reimbursed did not seem to lead to a difference in height outcome parameters. Therefore, we cannot give any recommendations on what policies seem to work best. Furthermore, the actual care provided by the doctors and their attitudes towards growth hormone therapy also affects height outcome, although data on growth hormone use are limited and no data are available on the duration of rGH treatment. We found that, in a few countries, outdated growth charts are applied, possibly leading to an underestimation of the growth retardation of individual children. Nevertheless, when using the outdated growth charts, still a minority of children eligible for receiving rGH, actually are receiving rGH.
The percentage of children receiving rGH in dialysis and transplantation showed a weak positive association with mean final height SDS, although this did not reach statistical significance. However, this might also be due to the cross-sectional nature of our study, limiting to draw conclusions on causeeffect relationships [40] .
Nevertheless, it is clinically relevant, as there is abundant data that rGH improves height. Furthermore, it suggests that, when rGH is not prescribed when actually indicated, other interventions to achieve an adult height within the normal range, such as optimal caloric intake, seem to fail.
CO N C L U S I O N
In this study, we aimed to quantify the variation in growth hormone policies in paediatric ESRD across European countries and their effect on height. We found considerable variation in policies regarding growth hormone between 28 European countries. Furthermore, rGH was significantly less often prescribed than would be expected, suggesting that outcome is not only affected by growth hormone policy, but also by other factors. Both doctors-and patient-related obstacles to prescribe rGH are amenable for interventions in order to improve the use of rGH in children with ESRD and offer those children a chance to achieve more beneficial health outcomes.
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